Skip to content

Cytokinetics CYTK Deferred Revenue

Deferred Revenue at other companies

Sanmina Corp logo
Sanmina CorpSANM
-$19.22M-109%
Sirius XM logo
Sirius XMSIRI
$974M-7.2%
Applied Digital logo
Applied DigitalAPLD
-$396K+96.0%
Bloom Energy logo
Bloom EnergyBE
$39.26M-16.8%
Sirius XM logo
Sirius XMSIRI
$0
Bloom Energy logo
Bloom EnergyBE
$194.09M+15.2%

Other financials

Income statement

See full
Revenue$19.4M+1,126%
Operating income-$183.6M-18.0%
Net income-$206.0M-27.7%
EPS (diluted)-$1.67-22.8%

Balance sheet

See full
Cash & equivalents$129.8M+76.2%
Total debt$418.2M+75.8%
Total equity-$826.6M-210%
Total assets$1.3B+0.7%

Cash flow

See full
Operating cash flow-$145.5M-10.5%
CapEx$5.9M+4.7%
Free cash flow-$151.4M-10.3%

Valuation

See full
Market cap$10.7B+70.6%
Enterprise value$10.98B+70.7%
P/S101.1×-225×

Profitability

See full
Operating margin-605.1%-268pp
Net margin-784%-337pp
FCF margin-518.8%-223pp

Returns & leverage

See full
Return on equity-337.6%
Debt / equity2.2×
Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.

The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytokinetics's deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytokinetics's deferred revenue?
Cytokinetics (CYTK) reported deferred revenue of $41K in Q1 2026.